Trevi Therapeutics, Inc.
TRVINASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $1.97B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $9.82$20.22
- Volume (live)
- -
- Avg. volume (3M)
- 2.48M
Trevi Therapeutics (TRVI) Stock Price & Financial Analysis
Trevi Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $12.39 - $12.74 |
|---|---|
| 52-Week High | $20.22 |
| 52-Week Low | $9.82 |
| Open | $12.74 |
| Volume (last close) | 1.38M |
| Average Volume (3M) | 2.48M |
| 50-Day MA | $15.52 |
|---|---|
| 200-Day MA | $14.27 |
| 1-Year Change | +21.50% |
| Market Cap | 1.97B |
|---|---|
| Shares Outstanding | 156.60M |
| Price to Book (P/B) | 6.14 |
| EV/EBITDA | -36.71 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Trevi Therapeutics at a Glance
As of the Oct 23, 2026 close, Trevi Therapeutics (TRVI) has a market capitalization of $1.97B.
As of its latest reported balance sheet, it holds $54.30M in cash and securities against $605.00K of debt, a net cash position of $53.70M.
Trevi Therapeutics does not currently pay a dividend.
The share price is up 21.5% over the past year. At $12.61 (the Oct 23, 2026 close) it sits within its 52-week range of $9.82 to $20.22, below its 200-day moving average of $14.27.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $29.00, 130.0% above the Oct 23, 2026 close.
Frequently Asked Questions About Trevi Therapeutics
What is the current stock price for TRVI?
As of the Oct 23, 2026 close, TRVI stock trades at $12.61. The 52-week range is $9.82–$20.22, with a day range of $12.39–$12.74.
What is the P/E ratio for TRVI?
The P/E ratio (Price-to-Earnings) for TRVI is shown in the Key Statistics section. This valuation metric helps compare Trevi Therapeutics, Inc. to industry peers.
Does TRVI pay dividends?
Trevi Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for TRVI?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for TRVI is Buy. The average 12-month price target is $29.00, a 130.0% upside from the Oct 23, 2026 close of $12.61.
What is the market cap of TRVI?
As of the Oct 23, 2026 close, Trevi Therapeutics's market capitalization is $1.97B, classifying it as a small-cap company. Trevi Therapeutics operates in the Healthcare sector within the Biotechnology industry.